Did Uber’s (UBER) $300 Million Lucid and Nuro Robotaxi Bet Just Shift Its Investment Narrative?

• Lucid Group recently announced a collaboration with Uber Technologies and Nuro to develop and deploy next-generation premium robotaxis on Uber’s ride-hailing platform, with Uber investing US$300 million and planning to roll out at least 20,000 Lucid Gravity vehicles equipped with Nuro autonomy over six years in global markets.
• This partnership positions Uber to accelerate its efforts in autonomous mobility and underscores its intent to compete in the rapidly evolving robotaxi sector through high-profile alliances and significant capital commitments.
• We'll examine how Uber's investment in autonomous vehicle deployment with Lucid and Nuro may reshape its investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Uber Technologies Investment Narrative Recap

To be an Uber Technologies shareholder, you need conviction in the company’s skill to grow its Mobility, Delivery, and autonomous offerings globally, while managing capital intensity and margin risk from expanding into AVs and premium partnerships like Lucid. The Lucid-Nuro robotaxi deal highlights Uber’s ongoing push to lead in autonomous mobility, but does not materially change the most immediate catalyst, which remains execution on quarterly user and gross bookings growth, nor does it reduce the biggest risk around AV commercialization timelines and profitability.

Among the recent updates, Uber’s Q3 2025 guidance for gross bookings, forecasting US$48.25 billion to US$49.75 billion, reflecting 17% to 21% YoY growth, directly ties to the primary short-term catalyst: proven user and spending growth at scale. These results remain central to offsetting the uncertainty and cost risk of autonomous vehicle investments, as investors watch the company’s ability to sustain core platform momentum alongside AV ambitions.

Yet, in contrast, investors should be aware that realizing profitability at scale in AV operations hinges on ...

Read the full narrative on Uber Technologies (it's free!)

Uber Technologies is projected to reach $71.1 billion in revenue and $9.7 billion in earnings by 2028. This outlook reflects a 14.5% annual revenue growth rate, but a decrease of $2.9 billion in earnings from the current $12.6 billion.

Uncover how Uber Technologies' forecasts yield a $106.08 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Fifty-six members of the Simply Wall St Community estimate Uber’s fair value between US$72.92 and US$160.19 per share, reflecting wide views on future growth and margin potential. With Uber’s capital-intensive push into AV partnerships such as Lucid and Nuro, it’s clear perspectives can vary greatly, explore other viewpoints to understand how such risks could shape returns.

Explore 56 other fair value estimates on Uber Technologies - why the stock might be worth as much as 73% more than the current price!

Build Your Own Uber Technologies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Uber Technologies research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Uber Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Uber Technologies' overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com